Durable Clinical Benefits in Transfusion-Dependent Β-Thalassemia with Exagamglogene Autotemcel
Haydar Frangoul(Children’s Hospital at TriStar Centennial), William Hobbs(Vertex Pharmaceuticals (United States)), Donna A. Wall(University of Manitoba), Amanda Li(BC Children's Hospital), Mattia Algeri(Bambino Gesù Children's Hospital), Franco Locatelli(Bambino Gesù Children's Hospital), Leorah Ross, Ben Carpenter(The Royal Free Hospital), Roland Meisel(Heinrich Heine University Düsseldorf), Sujit Sheth(Columbia University Irving Medical Center), Antonis Kattamis, Bo Tong(AbbVie (United States)), Peter Lang(STZ eyetrial), Kevin H.M. Kuo(University Health Network), Robert I. Liem(Lurie Children's Hospital), Ami J. Shah(University of California, Los Angeles), Hayley Merkeley(University of British Columbia), Maria Domenica Capellini(University of Milan), Stephan A. Grupp(Children's Hospital of Philadelphia), Gang Xu(University of Michigan), Selim Corbacioglu(Unknown), Janet L. Kwiatkowski(Children's Hospital of Philadelphia), Puja Kohli(Brigham and Women's Hospital), Josu de la Fuente(Imperial College Healthcare NHS Trust), Joachim Rupprecht(University of Tübingen), Markus Y. Mapara(Sheba Medical Center)
Cited by 1
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
|New England Journal of Medicine|2020|1.8k
Angiopoietin-1 protects the adult vasculature against plasma leakage
|Nature Medicine|2000|1.3k